Follow-Up for Barrett's Esophagus Without Dysplasia
For Barrett's esophagus without dysplasia, surveillance endoscopy should be performed every 3-5 years with four-quadrant biopsies taken every 2 cm, while maintaining once-daily proton pump inhibitor therapy. 1
Surveillance Protocol
Your pathology shows Barrett's mucosa (intestinal metaplasia) without dysplasia, which places you in the lowest-risk category for progression to esophageal adenocarcinoma. The annual cancer risk is only 0.1-0.3% per year 2, making aggressive surveillance unnecessary.
Endoscopic Surveillance Schedule
- Interval: Every 3-5 years 1, 2
- Technique: High-definition white-light endoscopy 3
- Biopsy protocol: Four-quadrant biopsies every 2 cm throughout the Barrett's segment 3
- Additional biopsies: Any visible mucosal irregularities (nodularity, ulceration) should be biopsied separately and submitted in distinct containers 3
Medical Management
Proton pump inhibitor (PPI) therapy is recommended at least once daily to reduce the risk of neoplastic progression 1. The 2025 AGA guideline emphasizes that PPIs serve dual purposes: controlling reflux symptoms and providing chemoprevention against progression to high-grade dysplasia or cancer. While observational evidence suggests PPIs may reduce progression risk, the absolute benefit is modest given the already low baseline risk in non-dysplastic Barrett's.
The dose should be adjusted to control reflux symptoms and heal any erosive esophagitis. Twice-daily dosing is not necessary unless symptoms require it 1.
Critical Caveats
Avoid Surveillance During Active Inflammation
Do not perform surveillance biopsies in the presence of severe erosive esophagitis (Los Angeles grade C or D) 4. Active inflammation can cause reactive changes that mimic dysplasia, leading to false-positive diagnoses. If biopsies must be obtained during inflammation, inform the pathologist of this context. Ideally, intensify acid suppression and repeat endoscopy after inflammation has resolved 4.
When to Escalate Surveillance
If future biopsies show low-grade dysplasia, the management changes dramatically:
- Confirm diagnosis with expert GI pathologist review 4
- Repeat endoscopy in 8-12 weeks on twice-daily PPI therapy 4
- If confirmed and persistent, surveillance increases to every 6 months for two examinations, then annually 4
- Consider endoscopic eradication therapy as an alternative to surveillance 5
Document Barrett's Extent
The Barrett's segment should be measured using the Prague classification (circumferential and maximal extent) 4. This standardized documentation helps track changes over time and guides biopsy protocols.
Lifestyle and Additional Considerations
While not proven to prevent progression, maintaining a healthy weight and avoiding tobacco are reasonable given their association with Barrett's development 2, 6. Aspirin or NSAIDs are not routinely recommended for chemoprevention in non-dysplastic Barrett's due to potential adverse effects outweighing uncertain benefits 1.
The key message: Your current finding requires only periodic surveillance every 3-5 years, not aggressive intervention. The vast majority of patients with non-dysplastic Barrett's never progress to cancer, making this a manageable condition with appropriate monitoring.